John Frank

Most Recent Articles by John Frank

Five things for pharma marketers to know: Tuesday, December 15, 2015

Five things for pharma marketers to know: Tuesday, December 15, 2015

By

Valeant agrees to cut prices in deal with Walgreens; FDA committee votes against Merck's Vytorin claims; Pacira settles off-label marketing case with the FDA

Five things for pharma marketers to know: Wednesday, December 9, 2015

Five things for pharma marketers to know: Wednesday, December 9, 2015

By

Pfizer reveals Ibrance pricing strategy; AMA call for DTC ban may resonate due to pricing debate; Baxalta's Vonvendi receives FDA approval

Five things for pharma marketers to know: Tuesday, December 1, 2015

Five things for pharma marketers to know: Tuesday, December 1, 2015

By

Gilead criticized over Sovaldi pricing strategy; analysis finds branded drugs cost more in the US; support is growing for Medicare negotiation of drug prices

Five things for pharma marketers to know: Tuesday, November 24, 2015

Five things for pharma marketers to know: Tuesday, November 24, 2015

By

Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease

Five things for pharma marketers to know: Wednesday, November 18, 2015

Five things for pharma marketers to know: Wednesday, November 18, 2015

By

Califf defends his past; Drug spending to increase by 4%-7% per year through 2020; Samsung Bioepis's Enbrel biosimilar faces decision-date Friday

More Articles by John Frank